IR Material - SpectraCure

Technology
Clinical study
Investors
Press
- Press releases
- News Letters
Team
Contact
English
- Svenska

Search

Shares
Ownership
Financial Calendar
Financial reports
Emissions
IR Material
Certified Adviser
Questions and answers

Invest deduction

Investeraravdrag 2020 SpectraCure (Swedish)

Investor letters

Investor letter June 2019
Investor letter December 2018
Investor letter April 2018
Investor letter December 2017
Investor letter October 2017

Shares
Ownership
Financial Calendar
Financial reports
Emissions
IR Material
Certified Adviser
Questions and answers

Invest deduction

Investeraravdrag 2020 SpectraCure (Swedish)

Investor letters

Investor letter June 2019
Investor letter December 2018
Investor letter April 2018
Investor letter December 2017
Investor letter October 2017

Pages

SpectraCure
Technology
Clinical study
Investors
Press
SpectraCure’s team
Contact with SpectraCure
Questions and answers

Investore Relations

Shares
Ownership
Financial Calendar
Financial reports
Emissions
IR Material
Certified Adviser
Questions and answers

Press

Press releases
News Letters

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.